OmniVision commences mass production of OV6930 medical image sensor

NewsGuard 100/100 Score

OmniVision Technologies, Inc. (Nasdaq: OVTI), a leading developer of advanced digital imaging solutions, today announced the initiation of mass production of the ultra-compact, high-performance OV6930.  With a packaged footprint of only 1.8 x 1.8 mm, the OV6930 is the ideal solution for applications favoring a small profile.  It is excellently suited to serve a broad range of medical endoscopy applications, including bronchoscopy, colonoscopy, gastroscopy, OB/GYN and urology, and can facilitate development of medical devices that require an outside diameter under 2.6 mm.  OmniVision also announced OV6930 design wins for two new medical device modules from Hong Kong based COMedia, Ltd.

"OmniVision's advanced digital imaging technologies offer significant potential advantages in the development of improved medical imaging applications that enable less invasive and more precise medical procedures," said James Lei, director of marketing for medical solutions for OmniVision.  "Additionally, our advanced pixel design and proven manufacturing process keep our products affordable, allowing medical devices to be made disposable while increasing patient safety, operating room hygiene and ease-of-use for medical practitioners."

The OV6930's unique architecture combines ultra-low power consumption with OmniVision's best-in-class pixel technology, OmniPixel3-HS™, enabling low-light performance of 3300 mV/lux-sec.  The 1/10-inch array is capable of operating up to 30 frames per second (fps) in 400 x 400 HVGA or 60 fps in 400 x 200 resolution, providing RAW serial output.  The low-voltage OV6930 allows cabling up to 14 ft.

The OV6930 will be on display at COMPAMED, November 17-19, 2010 at the Messe Dusseldorf in Dusseldorf, Germany where OmniVision will be exhibiting in Hall 8b, Stand E22.

The OV6930 is now shipping in volume to multiple customers.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionizing brain tumor treatment: the rise of AI in neuro-oncology